STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Q/C TECHNOLOGIES, INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Q/C Technologies, Inc. (QCLS)11,420 shares of common stock through a grant of restricted stock units at a price of $0 per share, bringing their directly held beneficial ownership to 12,500 shares. The RSUs were originally granted on 10/03/2025, subject to stockholder approval of an amendment to the company’s 2021 Equity Incentive Plan. Stockholders approved this plan amendment on 11/14/2025, and the RSUs vested immediately upon issuance.

Positive
  • None.
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Glass Mitchell

(Last) (First) (Middle)
1185 AVENUE OF THE AMERICAS,
SUITE 249

(Street)
NEW YORK NY 10036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Q/C TECHNOLOGIES, INC. [ QCLS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Director, Chief Medical Off.
3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 11/14/2025 A 11,420 A $0(1) 12,500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance.
/s/ Mitchell Glass 11/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Q/C Technologies (QCLS) report on this Form 4?

Q/C Technologies reported that a director and Chief Medical Officer acquired 11,420 shares of common stock via a grant of restricted stock units on 11/14/2025.

What is the reporting person’s new share ownership in Q/C Technologies (QCLS)?

After the reported transaction, the insider beneficially owns 12,500 shares of Q/C Technologies common stock in direct ownership.

At what price were the Q/C Technologies (QCLS) RSUs granted?

The 11,420 restricted stock units reported on the Form 4 were acquired at a stated price of $0 per share.

When were the Q/C Technologies (QCLS) RSUs originally granted and when did they vest?

The RSUs were originally granted on 10/03/2025 and vested immediately upon issuance after stockholder approval on 11/14/2025.

What plan governs the RSU grant reported by Q/C Technologies (QCLS)?

The RSU grant was made under the Q/C Technologies, Inc. 2021 Equity Incentive Plan, as amended by a plan amendment approved by stockholders.

What conditional approval was required for the Q/C Technologies (QCLS) RSUs?

The RSUs were subject to stockholder approval of a Plan Amendment to the 2021 Equity Incentive Plan, which was approved on 11/14/2025.

Q/C Technologies Inc

NASDAQ:QCLS

QCLS Rankings

QCLS Latest News

QCLS Latest SEC Filings

QCLS Stock Data

9.77M
3.95M
In Vitro & in Vivo Diagnostic Substances
NEW YORK